



## Diplomat Completes Acquisition of BioRx

April 1, 2015

---



Diplomat Pharmacy, Inc. (NYSE: DPLO), announced today it has completed the acquisition of BioRx, LLC, a highly specialized pharmacy and infusion services company that provides treatments for patients with ultra-orphan and rare, chronic diseases based in Cincinnati, Ohio. With the close of this acquisition, the combined resources and capabilities will make Diplomat one of the nation's largest specialty infusion providers.

Diplomat and BioRx are dedicated to personalized medication therapies for patients with chronic and complex therapies. Phil Hagerman, Chairman and CEO of Diplomat commented, "The combined resources of both companies will better serve our patients with broader access to limited distribution drugs as Diplomat and BioRx manage a strong therapy mix." Mr. Hagerman continued, "The combination furthers our capabilities to roll out services to a larger national geographic footprint which will strengthen our ties with pharmaceutical manufacturers by satisfying their demand for multi-channel reach."

"For payor partners, our expanded offering improves our ability to take care of patients regardless of benefits," said Phil Reilly, co-founder of BioRx. Eric Hill, co-founder of BioRx, furthered, "Since we started BioRx in 2004, our goal has been to build the country's most patient-centered specialty pharmacy. Diplomat shares this focus and continues to represent the right partner, at the right time, for us to continue our mission into the future."

Both BioRx co-founders, Phil Rielly and Eric Hill, have made multi-year commitments to help lead the combined infusion services organization going forward. In addition, all individuals and entities receiving Diplomat common stock as part of this transaction will be subject to certain lock-up restrictions on such shares, for at least six months after closing.

Under the terms of the agreement, Diplomat is paying BioRx \$210 million cash and approximately 4.05 million shares of Diplomat common stock. The transaction provides Diplomat with an expected future tax benefit of approximately \$50 million. Under the terms of a one-year contingent earnout, BioRx can earn an additional approximately 1.35 million shares of Diplomat common stock upon achieving an EBITDA-based metric. In 2014, BioRx generated approximately \$227 million in revenue and \$23 million in EBITDA. The transaction is expected to be accretive to Diplomat's earnings per share in the first full year following the closing of the transaction.

To learn more about Diplomat, visit [www.diplomat.is](http://www.diplomat.is).

*continues* ►



### *About Diplomat*

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues – always focused on improving patient care and clinical adherence.

### *About BioRx*

BioRx is a highly specialized provider of pharmacy and infusion services for patients with ultra-orphan and rare, chronic diseases. In addition to pharmacy and infusion services, BioRx also serves health plans and payer organizations with comprehensive data analytics and outcomes reporting. The company’s clinical staff reaches patients in all 50 states and operates dispensing facilities in Ohio, Massachusetts, North Carolina, Iowa, Minnesota, Arizona and California. To learn more, visit [www.biorx.com](http://www.biorx.com). ■

### *About Symmetric Capital*

Symmetric Capital, a private equity firm focused on profitable growth companies in the United States and Canada, invested in BioRx in 2010. With the flexibility to invest in either minority or majority positions, Symmetric structures transactions that meet both the immediate and the longer-term objectives of owners and managers – all without changing a company’s entrepreneurial culture or introducing excessive debt that restricts growth. Since 1990, Symmetric’s principals have built dozens of successful, collaborative partnerships, beginning in each case with an equity investment to fund growth, shareholder liquidity, debt repayment, a management-led buyout or a strategic acquisition.

Symmetric targets companies with at least \$10 million in revenues and \$2 million in operating profits. Sectors of interest include business and financial services, healthcare, technology, software, education, and consumer and industrial products. With over \$200 million in committed capital under management, Symmetric typically invests \$5-25 million in each company. Larger transactions can be funded in conjunction with our limited partners or with other co-investors. For more information on Symmetric, please visit [www.symmetriccapital.com](http://www.symmetriccapital.com).